Wide Ranks

BGNE

BeiGene, Ltd.

206.16

Top Statistics
Market Cap 22 B Forward PE -370.37 Revenue Growth 39.50 %
Current Ratio 1.94 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -25.50 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -49.15 Enterprise / Revenue 11.66 Price To Sales Trailing12 Months 0.9629
Profitability
Profit Margins -25.50 % Operating Margins -13.90 %
Balance Sheet
Total Cash 19 B Total Cash Per Share 13.74 Total Debt 7 B
Total Debt To Equity 30.55 Current Ratio 1.94 Book Value Per Share 226.72
All Measures
Short Ratio 342.00 % Message Board Id finmb_115205344 Shares Short Prior Month 1 M
Return On Equity -0.2322 City Camana Bay Uuid fa34b256-867c-3115-a0ac-dc5f85107a4b
Previous Close 192.11 First Trade Date Epoch Utc 1 B Book Value 226.72
Beta 0.6300 Total Debt 7 B Volume 341279
Price To Book 0.9093 Fifty Two Week Low 126.97 Total Cash Per Share 13.74
Total Revenue 23 B Shares Short Previous Month Date 1 B Target Median Price 287.00
Max Age 86400 Recommendation Mean 1.50 Sand P52 Week Change 0.3133
Operating Margins -13.90 % Target Mean Price 277.56 Net Income To Common -5993329664
Short Percent Of Float 0.0191 Implied Shares Outstanding 104 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 284180 Average Volume10days 284180
Total Cash 19 B Next Fiscal Year End 1 B Revenue Per Share 225.24
Held Percent Insiders 0.1947 Ebitda Margins -23.72 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 192.11
Target Low Price 152.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 212.01
Open 201.31 Free Cashflow -5262059520 Dividend Yield 0.00 %
Return On Assets -0.0958 Time Zone Short Name EST Trailing Eps -8.18
Day Low 201.03 Address1 94 Solaris Avenue Shares Outstanding 97 M
Price Hint 2 Target High Price 376.00 Website https://www.beigene.com
52 Week Change 0.1028 Average Volume 316439 Forward Eps -1.29
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 164.50 %
Is_sp_500 False Regular Market Day High 210.38 Profit Margins -25.50 %
Debt To Equity 30.55 Fifty Two Week High 248.16 Day High 210.38
Shares Short 999403 Regular Market Open 201.31 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 11.66 Revenue Growth 39.50 %
Shares Percent Shares Out 0.0094 Operating Cashflow -4558500864 Currency USD
Time Zone Full Name America/New_York Market Cap 22 B Is_nasdaq_100 False
Zip KY1-1108 Quote Type EQUITY Industry Biotechnology
Long Name BeiGene, Ltd. Regular Market Day Low 201.03 Held Percent Institutions 0.4922
Current Price 206.16 Enterprise To Ebitda -49.15 Financial Currency CNY
Current Ratio 1.94 Gross Margins 83.67 % Industry Disp Biotechnology
Number Of Analyst Opinions 22 Country Cayman Islands Float Shares 748 M
Two Hundred Day Average 175.71 Enterprise Value 274 B Price To Sales Trailing12 Months 0.9629
Forward PE -370.37 Regular Market Volume 341279 Ebitda -5576400384
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
BeiGene, Ltd.

, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.

The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.

It also has various preclinical programs.

The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co.

, Ltd.

; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.

; Amgen Inc.; and Beijing Novartis Pharma Co.

, Ltd.

BeiGene, Ltd.

was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.